🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,609 results for “AB” Clear

  1. PROGRAF 1 mg capsule, Envarsus 0.75 mg prolonged-release tablets

    Disc Medicine

    lung transplantation

    phase 3 small molecule active

    1 trial

  2. PROTAMINE CHOAY 1000 U.A.H./ml, solution injectable

    Pari Pharma GmbH

    Any patients ≥18 years old, eligible for transfemoral TAVI with coverage for medical insurance

    phase 3 small molecule active

    1 trial

  3. PRX-102

    Protalix BioTherapeutics

    Fabry Disease

    phase 3 small molecule completed

    2 trials

  4. PRX-102 (pegunigalsidase alfa)

    Protalix BioTherapeutics

    Fabry Disease

    phase 3 mab completed

    3 trials

  5. PSMA-11 kit for Ga-68 labelling

    Bial Portela & Companhia S.A.

    Intermediate and high-risk prostate cancer

    phase 3 small molecule active

    1 trial

  6. PTC923, Kuvan 100 mg soluble tablets, PTC923

    PTC THERAPEUTICS, INC.

    Phenylketonuria

    phase 3 small molecule active

    1 trial

  7. PTC923, PTC923

    PTC THERAPEUTICS, INC.

    Metabolic Disorders - Phenylketonuria

    phase 3 small molecule active

    1 trial

  8. PTM 300 mg tablets, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, PTM 75/50 mg FDC tablets, PTM 50/200/25 mg FDC tablets, Sunlenca 300 mg film-coated tablets, BICTEGRAVIR 75 MG/LENACAPAVIR 50 MG FDC TABLETS

    Gilead Sciences Pty Limited

    HIV-1 infection

    phase 3 small molecule active

    1 trial

  9. PVRV

    Sanofi Pasteur

    Rabies

    phase 3 mab completed

    1 trial

  10. Paclitaxel 6 mg/mL concentrate for solution for infusion, Javlor 25 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, Docetaxel Accord 80 mg/4 ml concentrate for solution for infusion

    Gilead Sciences Pty Limited

    Locally Advanced or Metastatic Unresectable Urothelial Cancer

    phase 3 small molecule active

    1 trial

  11. Paclitaxel 6mg/ml Concentrate for Solution for Infusion, Doxorubicin Teva 2 mg/ml Concentrate for Solution for Infusion, Fluorouracil 50 mg/ml Solution for Injection or Infusion, Tamoxifen 20 mg Tablets, Epirubicin 2 mg/ml Solution for Injection, Endoxana Injection 500 mg Powder for Solution for Injection, Anastrozole 1 mg film-coated tablets, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion

    Ningbo Cancer Hospital

    Patients with 1-3 positive Nodes, Hormone Receptor-Positive and Her2-Negative Breast Cancer with recurrence Score (RS) of 25 or Less

    phase 3 small molecule active

    1 trial

  12. Paclitaxel AqVida 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Abraxane 5 mg/ml powder for dispersion for infusion., Pemetrexed Accord 500 mg powder for concentrate for solution for infusion., Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., Cisplatino Accord Healthcare Italia 1 mg/ml concentrato per soluzione per infusione, Albotiva 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Bendatax 6 mg/ ml, Carboplatin Bendalis 10 mg/ml Konzentrat zur Herstellung

    Incyte

    Metastatic nonsquamous or squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  13. Paclitaxel Aurobindo 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Ipilimumab, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBOPLATIN, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, TAXOL 6 mg/ml, concentrato per soluzione per infusione., OPDIVO 10 mg/mL concentrate for solution for infusion., Paclitaxel-GRY® 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CISPL

    Bristol-Myers Squibb Australia Pty Ltd

    Stage IV Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  14. Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Abraxane 5 mg/ml powder for dispersion for infusion., Carboplatin 10 mg/ml concentrate for solution for infusion, Pazenir 5 mg/ml powder for dispersion for infusion, ivonescimab, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Summit Therapeutics

    Metastatic Squamous Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  15. Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine

    Teva Pharma GmbH

    Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

    phase 3 small molecule completed

    1 trial

  16. Pacritinib

    Swedish Orphan Biovitrum AB (publ)

    Primary Myelofibrosis

    phase 3 small molecule active

    1 trial

  17. Palazestrant matching placebo tablets and Letrozole matching placebo capsules, Palazestrant, RIBOCICLIB, Palazestrant, -, LETROZOLE , Palazestrant

    Olema Pharmaceuticals

    ER+, HER2- Advanced Breast Cancer

    phase 3 small molecule active

    1 trial

  18. Panitumumab

    Amgen

    Metastatic Colorectal Cancer

    phase 3 small molecule completed

    1 trial

  19. Parsabiv 5 mg solution for injection, Parsabiv 10 mg solution for injection

    Amgen

    Secondary hyperparathyroidism (SHPT) in pediatric patients with chronic kidney disease (CKD) in hemodialysis

    phase 3 small molecule active

    1 trial

  20. Pegunigalsidase alfa

    Protalix BioTherapeutics

    Fabry Disease

    phase 3 mab completed

    1 trial

  21. Pemazyre 9 mg tablets, Pemazyre 13.5 mg tablets, Pemazyre 4.5 mg tablets, Gemcitabine 1000 mg, powder for solution for infusion, Cisplatin Ebewe 1 mg/ml – Konzentrat zur Herstellung einer Infusionslösung

    Incyte

    Cholangiocarcinoma

    phase 3 small molecule active

    1 trial

  22. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Gastric Neoplasms

    phase 3 mab completed

    1 trial

  23. Pembrolizumab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 3 mab active

    1 trial

  24. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Solid Tumors

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources